Blueshift Asset Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Blueshift Asset Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-2,314	Closed	-$287K	–	355
2023 Q2	$287K	Buy	+2,314	New	+$311K	0.11%	229
2022 Q2	–	Sell	-1,699	Closed	-$264K	–	840
2022 Q1	$264K	Buy	1,699 +63	+4%	+$9.14K	0.02%	657
2021 Q4	$208K	Sell	1,636 -5,657	-78%	-$743K	0.02%	750
2021 Q3	$950K	Buy	7,293 +6,013	+470%	+$909K	0.05%	421
2021 Q2	$227K	Sell	1,280 -5,047	-80%	-$874K	0.01%	815
2021 Q1	$1.04M	Buy	6,327 +5,049	+395%	+$831K	0.11%	271
2020 Q4	$211K	Buy	+1,278	New	+$190K	0.03%	609
2019 Q1	–	Sell	-2,513	Closed	-$312K	–	830
2018 Q4	$312K	Buy	+2,513	New	+$373K	0.06%	479

Other funds holding JAZZ

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Samlyn Capital New York $6.14B AUM 42.05% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Blueshift Asset Management's JAZZ Position: Q3 2023 in Review

Blueshift Asset Management sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2023, closing a stake of 2,314 shares — an estimated $287K sold.

Blueshift Asset Management first reported a position in JAZZ in Q4 2018 and held it in 8 quarters. The position peaked at $1.04M in Q1 2021. 484 funds tracked by Wall St. Rank hold JAZZ as of Q3 2023.

Blueshift Asset Management reported no remaining Jazz Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
Blueshift Asset Management sold 2,314 Jazz Pharmaceuticals shares in Q3 2023, an estimated $287K.
Blueshift Asset Management first reported a position in Jazz Pharmaceuticals in Q4 2018 and held it in 8 quarters.
Blueshift Asset Management's Jazz Pharmaceuticals position peaked at $1.04M in Q1 2021.
484 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2023.

Based on Blueshift Asset Management's 13F filing for Q3 2023, filed 8 Nov 2023.